statistiche ricercatore

BARTALENA, LUIGI

Distribuzione geografica

Continente	#
NA - Nord America	24.074
EU - Europa	13.608
AS - Asia	7.002
SA - Sud America	846
AF - Africa	74
Continente sconosciuto - Info sul continente non disponibili	43
OC - Oceania	22
AN - Antartide	1
Totale	45.670

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	23.912
IT - Italia	6.338
UA - Ucraina	2.450
SG - Singapore	2.184
TR - Turchia	1.423
CN - Cina	1.137
DE - Germania	986
SE - Svezia	970
VN - Vietnam	965
HK - Hong Kong	884
BR - Brasile	706
IE - Irlanda	697
FI - Finlandia	616
GB - Regno Unito	598
RU - Federazione Russa	418
FR - Francia	130
IN - India	105
CA - Canada	100
JP - Giappone	94
NL - Olanda	56
AR - Argentina	50
MX - Messico	48
AT - Austria	46
ES - Italia	46
PL - Polonia	46
EU - Europa	41
BE - Belgio	36
CZ - Repubblica Ceca	36
BD - Bangladesh	35
ZA - Sudafrica	27
LT - Lituania	26
CL - Cile	24
ID - Indonesia	22
IQ - Iraq	22
EC - Ecuador	21
PK - Pakistan	21
CH - Svizzera	20
IL - Israele	16
RO - Romania	14
NZ - Nuova Zelanda	13
UZ - Uzbekistan	13
AE - Emirati Arabi Uniti	11
CO - Colombia	11
MA - Marocco	10
SA - Arabia Saudita	10
EG - Egitto	9
NP - Nepal	9
PY - Paraguay	9
VE - Venezuela	9
AU - Australia	8
BG - Bulgaria	8
BY - Bielorussia	8
HU - Ungheria	8
PE - Perù	8
KE - Kenya	7
MY - Malesia	7
DK - Danimarca	6
HR - Croazia	5
KR - Corea	5
LU - Lussemburgo	5
NO - Norvegia	5
PT - Portogallo	5
RS - Serbia	5
TN - Tunisia	5
UY - Uruguay	5
AZ - Azerbaigian	4
BA - Bosnia-Erzegovina	4
EE - Estonia	4
GR - Grecia	4
MD - Moldavia	4
PA - Panama	4
SK - Slovacchia (Repubblica Slovacca)	4
BN - Brunei Darussalam	3
HN - Honduras	3
JM - Giamaica	3
KW - Kuwait	3
LK - Sri Lanka	3
OM - Oman	3
SI - Slovenia	3
TH - Thailandia	3
TZ - Tanzania	3
A2 - ???statistics.table.value.countryCode.A2???	2
AM - Armenia	2
BH - Bahrain	2
BO - Bolivia	2
CI - Costa d'Avorio	2
DZ - Algeria	2
IR - Iran	2
KG - Kirghizistan	2
MM - Myanmar	2
PH - Filippine	2
SN - Senegal	2
AQ - Antartide	1
BT - Bhutan	1
CG - Congo	1
CV - Capo Verde	1
DO - Repubblica Dominicana	1
GA - Gabon	1
GE - Georgia	1
GL - Groenlandia	1
Totale	45.655

Salva come PNG Salva come JPEG

Città	#
Milan	4.548
Fairfield	3.210
Jacksonville	1.890
Woodbridge	1.867
Ashburn	1.841
Chandler	1.659
Houston	1.364
Seattle	1.329
Wilmington	1.241
Singapore	1.146
Cambridge	1.075
Dearborn	1.071
Ann Arbor	969
Dallas	931
Hong Kong	876
Izmir	724
Dublin	686
Princeton	674
Nyköping	416
Dong Ket	408
Boardman	396
Beijing	341
Rome	335
Como	237
San Mateo	237
Chicago	211
New York	205
San Diego	201
The Dalles	174
Los Angeles	136
Ogden	122
London	103
Tokyo	89
Düsseldorf	86
Hefei	82
São Paulo	78
Kunming	76
Santa Clara	75
Washington	69
Zhengzhou	67
Munich	63
Ho Chi Minh City	60
Kocaeli	60
Nanjing	60
Norwalk	60
Redmond	50
Hanoi	48
Warsaw	42
Helsinki	39
Guangzhou	38
Frankfurt am Main	37
Brussels	35
Shanghai	34
Jinan	33
Toronto	33
San Francisco	31
Stockholm	31
Verona	31
Denver	30
Montreal	30
Brooklyn	29
Brno	28
Vienna	26
Atlanta	25
Nanchang	25
Phoenix	25
Mexico City	24
Orem	24
Pune	21
Rio de Janeiro	21
North Bergen	20
Amsterdam	19
Turku	19
Kilburn	18
Madrid	18
Poplar	18
Johannesburg	17
Manchester	17
Berlin	16
Chennai	16
Varese	16
Ankara	15
Buffalo	15
Edinburgh	15
Boston	14
Curitiba	14
Hebei	14
Nuremberg	14
Shenyang	14
Chengdu	13
Redwood City	13
Tampa	13
Belo Horizonte	12
Buenos Aires	12
Miami	12
Salt Lake City	12
Acton	11
Changsha	11
Columbus	11
Tashkent	11
Totale	32.778

Salva come PNG Salva come JPEG

Nome	#
Vitreous Substitutes: The Present and the Future.	273
A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases.	259
Macular hole surgery: The healing process of outer retinal layers to visual acuity recovery	255
Simultaneous medullary and papillary thyroid cancer: two case reports.	233
A 2013 European survey of clinical practice patterns in the management of Graves' disease	230
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?	226
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	225
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	223
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	220
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	215
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	210
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	199
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012	199
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy	198
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere	196
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	196
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy	194
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	194
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	193
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO	191
Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone	191
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	188
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	187
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	186
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	185
Physical performance in newly diagnosed hypothyroidism: a pilot study	183
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	183
Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases	182
Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine	182
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	180
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	179
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	179
Lack of nocturnal serum thyrotropin surge after surgery	177
Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism	177
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	177
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?	176
The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?	176
Pain perception, blood pressure levels, and peripheral benzodiazepine receptors in patients followed for differentiated thyroid carcinoma: a longitudinal study in hypothyroidism and during hormone treatment	175
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.	174
Interference of thyroglobulin in TSAb detection by radioreceptor assay	173
More on smoking habits and Graves' ophthalmopathy	173
Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy	173
Studies on the occurrence of ophthalmopathy in Graves' disease	172
The effect of altered thyroid function on serum fructosamine concentrations	172
Radioactive iodine thyroid uptake in patients with amiodarone iodine-induced thyroid dysfunction	172
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives	172
Medullary thyroid carcinoma: surgical treatment advances	172
An update on medical management of Graves' ophthalmopathy	171
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism	171
Graves' orbitopathy: do not give it for granted	171
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	170
Amiodarone and the thyroid	170
Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells	169
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	169
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	169
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	165
Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight	165
Graves' disease and Turner's syndrome	164
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids	163
Shortening Hospital Stay for Thyroid Surgery.	163
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology consensus statement	163
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	163
Diagnosis of amiodarone iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness	162
Human serum thyrotrophin measurement by ultrasensitive immunoradiometric assay as a first-line test in the evaluation of thyroid function	161
Radioiodine therapy and Graves' ophthalmopathy	161
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	161
Graves' orbitopathy: imperfect treatments for a rare disease	161
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association	161
Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients	160
Changes in radioimmunoassayable prealbumin (TBPA) serum levels from birth to adulthood	160
Management of Graves' ophthalmopathy: reality and perspectives	160
Effects of the antileukemic drug L-asparaginase on sex-hormone binding globulin: studies in vivo and in vitro	159
Comparison between thyroid-stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease	159
2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction	159
Radioimmunoassay of thyroid hormones	157
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (Hep G2) cells	157
Effect of amiodarone on circulating antithyroid antibodies	157
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	156
Orbital radiotherapy for Graves' ophthalmopathy	156
Novel treatment modalities for Graves' orbitopathy	156
Cigarette smoking: Number one enemy for Graves ophthalmopathy	156
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement	156
Graves'-like orbitopathy: do not forget IgG4-related disease	156
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	156
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	155
Biosynthesis of a novel thyroxine-binding protein (27 K protein) in human hepatoma (Hep G2) cells	154
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	154
The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996	153
Ontogeny of nyctohemeral variations of thyrotropin-releasing hormone in rat hypothalamus	153
Thyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studies	153
Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells	151
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism	151
Long-term safety of orbital radiotherapy for Graves' ophthalmopathy	151
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature	151
Polymorphism of human thyroxine-binding globulin	150
High prevalence of subacute thyroiditis during summer season in Italy	150
An update on the pharmacological management of hyperthyroidism due to Graves' disease	150
Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: clinical evidence in thyroidectomized subjects on thyroxine replacement therapy.	150
Treatment of hyperthyroidism in patients with Graves' orbitopathy	150
Radioiodine therapy and Graves' ophthalmopathy	149
Totale	17.563

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	186.164
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	186.164

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	3.929	0	0	0	0	0	638	392	472	815	313	495	804
2021/2022	3.581	376	465	262	133	196	144	175	183	265	569	306	507
2022/2023	4.398	496	246	391	422	319	949	4	540	582	150	178	121
2023/2024	7.478	1.101	1.179	1.141	1.443	1.532	496	52	157	188	54	23	112
2024/2025	4.421	20	64	889	105	103	243	200	365	466	292	342	1.332
2025/2026	4.654	693	730	747	1.311	1.010	163	0	0	0	0	0	0
Totale													45.916